Stephanie Graff, MD, FACP, FASCO· @DrSGraff · X·· 22 hours agoScore70
Body · original
VIKTORIA-1 shows benefit of Gedatolisib + fulvestrant +/- palbociclib significantly improved median PFS across subgroups as compared to alpelisb+fulv (in second line after CDK4/6i) #ESMO26 @OncoAlert @BarbaraPistill2
137 views · 5 likes · 4 reposts · 0 replies
Conference abstracts
LBA16matched by Rapid oral 1: Breast cancer, advanced stage
VIKTORIA-1: Updated results of a randomized, open-label, phase 3 study of gedatolisib (geda) + fulvestrant (fulv) ± palbociclib (palbo) vs standard of care in patients (pts) with HR+/HER2- advanced breast cancer (ABC) (Study 2)
https://esmocongress.esmo.orgSource: Stephanie Graff, MD, FACP, FASCO · x.com